Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA/ISOPP 2019 | Biosimilars in pharmacy practice: trastuzumab, rituximab and beyond

Rob Duncombe • 10 Oct 2019
BOPA/ISOPP 2019
Rituximab Trastuzumab

Biosimilars can bring many benefits; here, Rob Duncombe, of the Christie NHS Foundation Trust, Manchester, UK, discusses the biosimilars currently being used in cancer treatment, and the key role of pharmacists in their implementation and usage. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

More from Rob Duncombe

0:50
How may Brexit impact pharmacy?
Rob Duncombe • 10 Oct 2019
1:43
Demand for oncology pharmacists in the clinic
Rob Duncombe • 10 Oct 2019
1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe • 10 Oct 2019
1:03
Global oncology pharmacy collaboration: ISOPP and BOPA
Rob Duncombe • 10 Oct 2019
The content of VJOncology is intended for healthcare professionals